bullish
JD Health (6618.HK) 2021 Results - The Logic and the Outlook
272 Views06 Apr 2022 08:55
The service revenue has larger potential and is complementary to product revenue.Due to the essence of medical attributes,even if JD Health's online healthcare services fails, it could still stand out
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Pre-IPO Beijing Yuanxin Technology Group - Conservative About the Outlook17 Jun 2022
- China Healthcare Weekly (Apr.8)-Surgical Robots Pricing Rules,America COMPETES Act,COVID-19 Sequelae10 Apr 2022
- Medlive Technology (2192.HK) - The Logic Has Shaken07 Apr 2022
- JD Health (6618.HK) 2021 Results - The Logic and the Outlook06 Apr 2022
- Innovent Biologics Inc (1801.HK) - Capable of Surviving “this Winter”04 Apr 2022
- Ping An Good Doctor (1833.HK) - A Vicious Cycle?30 Aug 2021
- JD Health (6618.HK) - Opportunities Coexist with Challenges15 Dec 2020
x